NDA 019684 · Pfizer
Procardia Xl
Nifedipine · Oral · Dihydropyridine Calcium Channel Blocker
Last checked: Nov 19, 2026Latest source record: Nov 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Sep 6, 1989
Approved uses
1
Original approval plus efficacy supplements
Registered trials
168
39 Phase 3, 11 recruiting
FAERS reports
47,621
36,714 serious, 5,300 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 21, 2026.
INDICATIONS AND USAGE Vasospastic Angina PROCARDIA XL is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA XL may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. Chronic Stable Angina (Classical Effort-Associated Angina) PROCARDIA XL is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict...
Mechanism: Mechanism of Action A) Angina The precise mechanisms by which inhibition of calcium influx relieves angina has not been fully determined, but includes at least the following two mechanisms: 1) Relaxation and Prevention of Coronary Artery Spasm Nifedipine dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with coronary artery spasm and is responsible for the effectiveness of nifedipine in...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 6, 1989 Original approval · Type 3 - New Dosage Form
3 products under this application
- PROCARDIA XL · NIFEDIPINE 60MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB2
- PROCARDIA XL · NIFEDIPINE 90MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB2
- PROCARDIA XL · NIFEDIPINE 30MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB2
Clinical trials
Interventional ClinicalTrials.gov studies with "Nifedipine" as an intervention, any sponsor and status, largest first.
- Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST TrialPivotal-lookingNot yet recruiting
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT07746271 · 4,120 participants (planned) · Start Sep 30, 2026 · Primary completion Dec 31, 2029
Drug: Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg · For: Hypertension in Pregnancy; Obstetrical Complications
Sites: Birmingham, Alabama; San Francisco, California; Chicago, Illinois · 14 sites in all
- Standard Medical Management in Secondary Prevention of Ischemic Stroke in ChinaPivotal-lookingCompleted
Peking Union Medical College HospitalAcademic, hospital or other
NCT00664846 · 4,000 participants (planned) · Start Apr 2008 · Primary completion Dec 2010
Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Asprin / Clopidogrel, Atorvastatin / Simvastatin · For: Stroke
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 46 sites in all
- Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationPivotal-lookingNot yet recruiting
Tibet Autonomous Region People's HospitalAcademic, hospital or other
NCT07639931 · 3,035 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 20, 2028
Drug: Multicenter study of HAPE group:NO Group · For: Severe High Altitude Pulmonary Edema; Severe High Altitude Cerebral Edema
Sites: Lhasa, China
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- Chronic Hypertension and Pregnancy (CHAP) ProjectPivotal-lookingCompleted
University of Alabama at BirminghamAcademic, hospital or other
NCT02299414 · 2,408 participants · Start Jun 2015 · Primary completion Apr 1, 2022
Drug: Anti-hypertensive therapy · For: Hypertension
Sites: Birmingham, Alabama; Mobile, Alabama; Little Rock, Arkansas · 72 sites in all
- Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With NormoalbuminuriaPivotal-lookingStatus unknown
Hospital Authority, Hong KongGovernment (non-federal)
NCT01500590 · 1,400 participants · Start Nov 2011 · Primary completion Aug 2018
Drug: Renin-angiotensin system blockers; non-renin angiotensin system blockers · For: Diabetes; Hypertensive Disease
Sites: Hong Kong, China
- Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential HypertensionPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01303783 · 1,381 participants · Start Apr 2011 · Primary completion May 2012
Drug: Candesartan cilexetil (Atacand), 4 mg; Candesartan cilexetil (Atacand), 8 mg and 6 more · For: Hypertension, Essential
Sites: Mobile, Alabama; Los Angeles, California; Coral Gables, Florida · 157 sites in all
- The Standardized Management of Hypertension in Rural ShaanxiPivotal-lookingCompleted
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT04371874 · 1,210 participants · Start Jan 2014 · Primary completion Jul 2017
Drug: Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin · For: Hypertension
Sites: Xi'an, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,641
- dyspnoea2,507
- fatigue2,421
- diarrhoea2,388
- nausea2,320
- off label use2,171
- headache2,101
- dizziness1,846
- hypertension1,835
- pain1,739
- death1,565
- asthenia1,539
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 951 |
| 2005 | 1,016 |
| 2006 | 1,021 |
| 2007 | 777 |
| 2008 | 937 |
| 2009 | 1,038 |
| 2010 | 1,287 |
| 2011 | 1,445 |
| 2012 | 1,576 |
| 2013 | 1,306 |
| 2014 | 1,727 |
| 2015 | 2,093 |
| 2016 | 2,537 |
| 2017 | 2,782 |
| 2018 | 3,241 |
| 2019 | 3,663 |
| 2020 | 3,286 |
| 2021 | 3,017 |
| 2022 | 2,926 |
| 2023 | 2,986 |
| 2024 | 3,075 |
| 2025 | 2,834 |
| 2026 | 2,094 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Procardia XL (Nifedipine)
2024 spending
$979K
Beneficiaries
396
1,214 claims
Per beneficiary
$2,471
$10.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,984,239 |
| 2021 | $2,627,377 |
| 2022 | $2,203,078 |
| 2023 | $2,006,051 |
| 2024 | $978,592 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral antihypertensive treatment during pregnancy: a systematic review and network meta-analysis.
Hup RJ, Damen JAA, Terstappen J, et al. · Am J Obstet Gynecol 2025 · Network Meta-Analysis, Systematic Review
- Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis.
Yin J, Mei Z, Shi S, et al. · Arch Gynecol Obstet 2022 · Meta-Analysis, Systematic Review
- Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis.
Liang L, Kung JY, Mitchelmore B, et al. · J Clin Hypertens (Greenwich) 2022 · Systematic Review, Network Meta-Analysis
- Systematic review and meta-analysis of randomized controlled trials of atosiban versus nifedipine for inhibition of preterm labor.
Ali AA, Sayed AK, El Sherif L, et al. · Int J Gynaecol Obstet 2019 · Meta-Analysis, Systematic Review
- Isosorbide and nifedipine for Chagas' megaesophagus: A systematic review and meta-analysis.
Borges Migliavaca C, Stein C, Colpani V, et al. · PLoS Negl Trop Dis 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Postpartum management of the hypertensive disorders of pregnancy: a systematic review and meta-analysis.
Tol ID, Khalil A, Cairns AE, et al. · Am J Obstet Gynecol 2026 · Systematic Review, Meta-Analysis
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.